Comparison of Fatal or Irreversible Events With Extended-Duration Betrixaban Versus Standard Dose Enoxaparin in Acutely III Medical Patients: An APEX Trial Substudy


Gibson C. M. , Korjian S., Chi G., Daaboul Y., Jain P., Arbetter D., ...Daha Fazla

JOURNAL OF THE AMERICAN HEART ASSOCIATION, cilt.6, 2017 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Cilt numarası: 6 Konu: 7
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1161/jaha.117.006015
  • Dergi Adı: JOURNAL OF THE AMERICAN HEART ASSOCIATION

Özet

Background-Extended-duration betrixaban showed a significant reduction in venous thromboembolism in the APEX trial (Acute Medically III VTE Prevention With Extended Duration Betrixaban Study). Given the variable clinical impact of different efficacy and safety events, one approach to assess net clinical outcomes is to include only those events that are either fatal or cause irreversible harm.